Hedgehog Pathway Inhibition Hampers Sphere and Holoclone Formation in Rhabdomyosarcoma

Altres autors/es

Institut Català de la Salut

[Almazán-Moga A, Zarzosa P, Vidal I, Molist C, Giralt I, Navarro N, Soriano A, Segura MF, Roma J] Grup de Recerca translacional en càncer infantil, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Sánchez de Toledo J, Gallego S] Grup de Recerca translacional en càncer infantil, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Oncologia i Hematologia Pediàtriques, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain

Vall d'Hebron Barcelona Hospital Campus

Data de publicació

2021-04-22T11:29:00Z

2021-04-22T11:29:00Z

2017-01-24

Resum

Tumors dels teixits tous; Via Hedgehog; Rabdomiosarcoma


Tumores de los tejidos blandos; Vía Hedgehog; Rabdomiosarcoma


Soft tissue neoplasms; Hedgehog pathway; Rhabdomyosarcoma


Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children and can be divided into two main subtypes: embryonal (eRMS) and alveolar (aRMS). Among the cellular heterogeneity of tumors, the existence of a small fraction of cells called cancer stem cells (CSC), thought to be responsible for the onset and propagation of cancer, has been demonstrated in some neoplasia. Although the existence of CSC has been reported for eRMS, their existence in aRMS, the most malignant subtype, has not been demonstrated to date. Given the lack of suitable markers to identify this subpopulation in aRMS, we used cancer stem cell-enriched supracellular structures (spheres and holoclones) to study this subpopulation. This strategy allowed us to demonstrate the capacity of both aRMS and eRMS cells to form these structures and retain self-renewal capacity. Furthermore, cells contained in spheres and holoclones showed significant Hedgehog pathway induction, the inhibition of which (pharmacologic or genetic) impairs the formation of both holoclones and spheres. Our findings point to a crucial role of this pathway in the maintenance of these structures and suggest that Hedgehog pathway targeting in CSC may have great potential in preventing local relapses and metastases.


The authors wish to thank Dr. Noel Monks (MedImmune) for the kind gift of the blocking antibody MEDI-5304 and Ms. Christine O’Hara for help with the English version of this manuscript. This work was supported by grants from Institut Català d’Oncologia (ICO), Instituto de Salud Carlos III (RTICC-RD12/0036/0016 and RD12/0036/0027; PI11/00740 and PI14/00647), Fundació A. BOSCH, and ajuts predoctorals VHIR.

Tipus de document

Article


Versió publicada

Llengua

Anglès

Publicat per

Hindawi

Documents relacionats

Stem Cells International;2017

https://www.hindawi.com/journals/sci/2017/7507380/

info:eu-repo/grantAgreement/ES/1PN/2008-2011/RD12%2F0036%2F0016

info:eu-repo/grantAgreement/ES/2PN/2008-2011/PI11%2F00740

info:eu-repo/grantAgreement/ES/PE2013-2016/PI14%2F00647

Citació recomanada

Aquesta citació s'ha generat automàticament.

Drets

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

Aquest element apareix en la col·lecció o col·leccions següent(s)